TY - JOUR
T1 - Expression of oestrogen and luteinising hormone receptor in testis cancer
AU - Giwercman, A.
AU - Dizeyi, N.
AU - Bjartell, A.
AU - Teerds, K.J.
PY - 2006
Y1 - 2006
N2 - INTRODUCTION & OBJECTIVES: Sex steroids and/or gonadotropins are believed
to play an important role in pathogenesis of testicular germ cell cancer (TGCC).
Whereas expression of the androgen receptor was found in carcinoma-in-situ testis (CIS)
and in seminomas, such information regarding oestrogen and gonadotropin receptors
is lacking. The aim of present study was, therefore, to map possible expression of the
oestrogen receptor beta (ERß) and luteinising hormone receptor (LHR) in CIS and in
seminomas (S) as well as non-seminomas (NS).
MATERIAL & METHODS: Immunohistochemistry was used to localize the
expression of ERß and LHR in 26 archival testicular cancers and 4 morphologically
normal testes. Expression of the steroid receptors at the transcript level was assessed
by in situ hybridisation in 3 specimens of normal testis and in corresponding number
of tumours.
RESULTS: Expression of ERß at protein level was shown in 13/13 S, 5/5 CIS adjacent
to S, 6/13 NS and 7/12 CIS adjacent to NS. In NS, the ERß expression was mainly
found in teratomas and endodermal sinus tumours and to a less degree in embryonal
carcinomas. Immunohistochemistry data were, thereafter, confi rmed by in situ
hybridisation. Expression of LHR was found in 4/4 non-seminomas and 1/7 seminomas.
LHR was also localised in spermatagonia of the normal testis.
CONCLUSIONS: Our results provide the fi rst evidence that ER-ß is highly expressed
in S. Its expression is less pronounced in NS, mainly embryonal cell carcinomas but
remains high in endodermal sinus tumours and in teratomas. LHR was occasionally
expressed in NS tumour cells. Collectively, these fi ndings provide a possible link
between steroid hormone/gonadotropin exposure and testicular cancer pathogenesis, an
the differences in receptor expression between S and NS, might at least partly explain
the discrepancý in age-related incidence and metastasing capacity of these two subtypes
of TGCC.
AB - INTRODUCTION & OBJECTIVES: Sex steroids and/or gonadotropins are believed
to play an important role in pathogenesis of testicular germ cell cancer (TGCC).
Whereas expression of the androgen receptor was found in carcinoma-in-situ testis (CIS)
and in seminomas, such information regarding oestrogen and gonadotropin receptors
is lacking. The aim of present study was, therefore, to map possible expression of the
oestrogen receptor beta (ERß) and luteinising hormone receptor (LHR) in CIS and in
seminomas (S) as well as non-seminomas (NS).
MATERIAL & METHODS: Immunohistochemistry was used to localize the
expression of ERß and LHR in 26 archival testicular cancers and 4 morphologically
normal testes. Expression of the steroid receptors at the transcript level was assessed
by in situ hybridisation in 3 specimens of normal testis and in corresponding number
of tumours.
RESULTS: Expression of ERß at protein level was shown in 13/13 S, 5/5 CIS adjacent
to S, 6/13 NS and 7/12 CIS adjacent to NS. In NS, the ERß expression was mainly
found in teratomas and endodermal sinus tumours and to a less degree in embryonal
carcinomas. Immunohistochemistry data were, thereafter, confi rmed by in situ
hybridisation. Expression of LHR was found in 4/4 non-seminomas and 1/7 seminomas.
LHR was also localised in spermatagonia of the normal testis.
CONCLUSIONS: Our results provide the fi rst evidence that ER-ß is highly expressed
in S. Its expression is less pronounced in NS, mainly embryonal cell carcinomas but
remains high in endodermal sinus tumours and in teratomas. LHR was occasionally
expressed in NS tumour cells. Collectively, these fi ndings provide a possible link
between steroid hormone/gonadotropin exposure and testicular cancer pathogenesis, an
the differences in receptor expression between S and NS, might at least partly explain
the discrepancý in age-related incidence and metastasing capacity of these two subtypes
of TGCC.
U2 - 10.1016/S1569-9056(06)60262-5
DO - 10.1016/S1569-9056(06)60262-5
M3 - Abstract
SN - 0302-2838
VL - 5
SP - 86
EP - 86
JO - European Urology
JF - European Urology
IS - 2
ER -